Scientific Program
Thursday, October 17, 2019
17:00 – 17:10 | Break |
17:10 – 18:10 | Symposium: Re-assessing the ESCEO algorithm for knee OA in the long-term perspective Supported by Mylan |
Hall A |
Chairpersons | Wen-Chan Tsai, Taiwan Chung-Hwan Chen, Taiwan |
|
17:10 | Evidence for the long-term pharmacological management of osteoarthritis Lucio Rovati, Italy |
|
17:30 | Treating osteoarthritis symptoms with symptomatic slow acting drugs for osteoarthritis (SYSADOAs): Update on most recent guidelines Jean-Pierre Pelletier, Canada |
|
17:50 | Q&A/Discussion |
Friday, October 18, 2019
09:45 – 10:05 | Coffee Break and Poster Viewing |
12:05 – 12:20 | Lunch Break and Poster Viewing |
12:20 – 13:20 | Industry Symposium: Expansion of treatment Options in RA Supported by Celltrion |
Hall A |
Chairperson | Wen-Chan Tsai, Taiwan | |
12:20 – 12:25 | Welcome and Introduction Wen-Chan Tsai, Taiwan |
|
12:25 – 12:40 | The truth of biosimilar against clinicians’ concern Tore K. Kvien, Norway |
|
12:40 – 12:55 | Future of biosimilar infliximab and global status Tore K. Kvien, Norway |
|
12:55 – 13:10 | Compelling clinical evidence from real world data Aileen Agbanlog, Philippines |
|
13:10 – 13:20 | Panel Discussion |
15:20 – 15:40 | Coffee Break and Poster Viewing |
16:40 | Poster Session and Refreshments |
Saturday, October 19, 2019
09:35 – 10:00 | Coffee Break and Poster Viewing |
11:00 – 12:00 | Industry Symposium: The many faces of Janus Kinase inhibitors in rheumatology Supported by Pfizer |
Hall A |
Chairperson | Wen-Chan Tsai, Taiwan | |
11:00 | Mechanisms of action and rational for the use of JAK inhibitors in RA and PsA Tsutomu Takeuchi, Japan |
|
11:20 | How to best use the JAK inhibitors: Lessons learned from the clinical trials and real life use Boulos Haraoui, Canada |
|
11:40 | Q&A/Discussion |
12:00 – 13:00 | Lunch Break and Poster Viewing |
14:30 – 14:45 | Coffee Break and Poster Viewing |